Research Progress on Stimulus-Responsive Polymer Nanocarriers for Cancer Treatment

Luo, Shao-Liu; Lv, Zhenbo; Yang, Qin; Chang, Ruidong; Wu, Junzi

doi:10.3390/pharmaceutics15071928

Cited by 13 publications

(6 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, LA67 has poor solubility in water, weak permeability, and poor bioavailability. Encapsulating hydrophobic drugs in nanocarriers has always been an excellent solution to overcome its low solubility and can also improve its pharmacological activity [ 33 ]. Therefore, in this study, we optimized an LNP formulation for encapsulating the hydrophobic drug LA67 to enhance its water solubility, bioavailability, and efficient delivery into the keloid environment.…”

Section: Discussionmentioning

confidence: 99%

LA67 Liposome-Loaded Thermo-Sensitive Hydrogel with Active Targeting for Efficient Treatment of Keloid via Peritumoral Injection

Wan,

Wang,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

A keloid is a benign tumor manifested as abnormal fibroplasia on the surface of the skin. Curing keloids has become a major clinical challenge, and searching for new treatments and medications has become critical. In this study, we developed a LA67 liposome-loaded thermo-sensitive hydrogel (LA67-RL-Gel) with active targeting for treating keloids via peritumoral injection and explored the anti-keloid mechanism. Firstly, Arg-Gly-Asp (RGD) peptide-modified liposomes (LA67-RL) loaded with LA67 were prepared with a particle size of 105.9 nm and a Zeta potential of −27.4 mV, and an encapsulation efficiency of 89.6 ± 3.7%. We then constructed a thermo-sensitive hydrogel loaded with LA67-RL by poloxamer 407 and 188. The formulation was optimized through the Box–Behnken design, where the impact of the proportion of the ingredients on the quality of the hydrogel was evaluated entirely. The optimal formulation was 20.7% P407 and 2.1% P188, and the gelation time at 37 °C was 9.5 s. LA67-RL-Gel slowly released 92.2 ± 0.8% of LA67 at pH 6.5 PBS for 72 h. LA67-RL-Gel increased adhesion with KF cells; increased uptake; promoted KF cells apoptosis; inhibited cell proliferation; reduced α-SMA content; decreased collagen I, collagen III, and fibronectin deposition; inhibited angiogenesis; and modulated the keloid microenvironment, ultimately exerting anti-keloid effects. In summary, this simple, low-cost, and highly effective anti-keloid liposome hydrogel provides a novel approach for treating keloids and deserves further development.

show abstract

Section: Discussionmentioning

confidence: 99%

LA67 Liposome-Loaded Thermo-Sensitive Hydrogel with Active Targeting for Efficient Treatment of Keloid via Peritumoral Injection

Wan,

Wang,

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…88 Additionally, in a clinical trial that received paclitaxel liposomal chemotherapy in combination with a PD-1/PD-L1 inhibitor as a first-line therapeutic agent, treatment-related adverse events of any grade were still observed in 25 patients, and adverse events of grade 3 or worse were observed in 9 patients. 89 Therefore, the cocktail combination of ICD inducers with ICIs are not universally applicable in clinical practice.…”

Section: Advantages Of Combination Of Icd Inducers and Pd-1/pd-l1 Inh...mentioning

confidence: 99%

Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy

Zhang,

Fang,

Guo

et al. 2024

IJN

View full text Add to dashboard Cite

Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through the inhibition of tumor immune evasion pathways, ultimately leading to the initiation of an antitumor immune response. However, the clinical implementation of ICIs encounters obstacles stemming from the existence of an immunosuppressive tumor microenvironment and inadequate infiltration of CD8 + T cells. Considerable attention has been directed towards advancing immunogenic cell death (ICD) as a potential solution to counteract tumor cell infiltration and the immunosuppressive tumor microenvironment. This approach holds promise in transforming "cold" tumors into "hot" tumors that exhibit responsiveness to antitumor. By combining ICD with ICIs, a synergistic immune response against tumors can be achieved. However, the combination of ICD inducers and PD-1/PD-L1 inhibitors is hindered by issues such as poor targeting and uncontrolled drug release. An advantageous solution presented by stimulus-responsive nanocarrier is integrating the physicochemical properties of ICD inducers and PD-1/PD-L1 inhibitors, facilitating precise delivery to specific tissues for optimal combination therapy. Moreover, these nanocarriers leverage the distinct features of the tumor microenvironment to accomplish controlled drug release and regulate the kinetics of drug delivery. This article aims to investigate the advancement of stimulus-responsive co-delivery nanocarriers utilizing ICD and PD-1/PD-L1 inhibitors. Special focus is dedicated to exploring the advantages and recent advancements of this system in enabling the combination of ICIs and ICD inducers. The molecular mechanisms of ICD and ICIs are concisely summarized. In conclusion, we examine the potential research prospects and challenges that could greatly enhance immunotherapeutic approaches for cancer treatment.

show abstract

“…While carrying out radical polymerization of N-isopropyl acrylamide (NIPAAm), it is common practice to make use of the initiator known as azobis(isobutyronitrile). Thermo-responsive polymers have a variety of applications in biological and medical fields, including medicine and gene trans-fer [39]. An investigation was conducted into the temperature dependence of the swelling of cross-linked poly(N,N-alkyl substituted acrylamides) in water.…”

Section: Poly(n-isopropyl Acrylamide)mentioning

confidence: 99%

“…Polymers 2023, 15, x FOR PEER REVIEW 6 of 45 of applications in biological and medical fields, including medicine and gene transfer [39].…”

Section: Poly(ethylenimine)mentioning

confidence: 99%

Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials

Harun-Or-Rashid,

Aktar,

Hossain

et al. 2023

Polymers

View full text Add to dashboard Cite

Polymeric drug delivery technology, which allows for medicinal ingredients to enter a cell more easily, has advanced considerably in recent decades. Innovative medication delivery strategies use biodegradable and bio-reducible polymers, and progress in the field has been accelerated by future possible research applications. Natural polymers utilized in polymeric drug delivery systems include arginine, chitosan, dextrin, polysaccharides, poly(glycolic acid), poly(lactic acid), and hyaluronic acid. Additionally, poly(2-hydroxyethyl methacrylate), poly(N-isopropyl acrylamide), poly(ethylenimine), dendritic polymers, biodegradable polymers, and bioabsorbable polymers as well as biomimetic and bio-related polymeric systems and drug-free macromolecular therapies have been employed in polymeric drug delivery. Different synthetic and natural biomaterials are in the clinical phase to mitigate different diseases. Drug delivery methods using natural and synthetic polymers are becoming increasingly common in the pharmaceutical industry, with biocompatible and bio-related copolymers and dendrimers having helped cure cancer as drug delivery systems. This review discusses all the above components and how, by combining synthetic and biological approaches, micro- and nano-drug delivery systems can result in revolutionary polymeric drug and gene delivery devices.

show abstract

Research Progress on Stimulus-Responsive Polymer Nanocarriers for Cancer Treatment

Cited by 13 publications

References 152 publications

LA67 Liposome-Loaded Thermo-Sensitive Hydrogel with Active Targeting for Efficient Treatment of Keloid via Peritumoral Injection

LA67 Liposome-Loaded Thermo-Sensitive Hydrogel with Active Targeting for Efficient Treatment of Keloid via Peritumoral Injection

Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy

Recent Advances in Micro- and Nano-Drug Delivery Systems Based on Natural and Synthetic Biomaterials

Contact Info

Product

Resources

About